Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist
The DOI matches its Crossref record; 42 of the 44 references it cites were found in a registry or an index.
Abstract
CD4+CD25+ T cells play a central role in the suppression of autoimmunity and inflammation, making their in vivo expansion a highly attractive therapeutic target. By phenotyping with a novel rat CTL antigen‐4 (CTLA‐4)‐specific monoclonal antibody (mAb) and functional in vitro assays, we here first establish that rat CD4+CD25+ T cells correspond to the regulatory T cells (T reg cells) described in mice and humans: they constitutively express CTLA‐4, produce IL‐10 but not IL‐2, and are able to suppress the proliferation of costimulated CD25‐negative indicator cells. Furthermore, we show that rat T reg cells respond less well than CD25– T cells to conventional costimulation, but are readily expanded in vitro with "superagonistic" CD28‐specific mAb which are potent mitogens for all T cells without the need for TCR engagement. In vivo, functional T reg cells are preferentially expanded by CD28 stimulation over other T cell subsets, leading to a 20‐fold increase within 3 days in response to a single antibody dose. These data suggest that CD28‐driven activation of T reg cells may be highly effective in the treatment of inflammatory and autoimmune diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In rodent models, treatment with CD28 superagonists orthologous to TGN1412 stimulated the release of anti-inflammatory cytokines and the expansion of regulatory T-cells believed to counter autoimmune responses (Rodríguez-Palmero et al., 1999;Lin and Hünig, 2003;Beyersdorf et al., 2005).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Lin and Hünig, 2003
In the citing paper
“injection of such 'superagonistic (SA)' mAbs (also called CD28 superagonists, CD28SA) into rats resulted in a preferential activation and expansion of a subset of CD4 T cells called regulatory T cells (Treg cells) [2]”
From The rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account (2016) · cites this paper as [2]
In the citing paper
“Rapid expansion of regulatory T cells (here defined by FACS analyses as CD4+ CD25+ cells among splenic lymphocytes) in rats after a single injection of the rat-specific CD28SA JJ316.Modified from Ref.[2].”
From The rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account (2016) · cites this paper as [2]
Citations
Cites
Interleukin-10 and the Interleukin-10 Receptor
Moore, K. W., de Waal Malefyt, R., Coffman, R. L., & O'Garra, A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.683 · Cited by 6,737
Park, J.-H., Adoro, S., Guinter, T., Erman, B., Alag, A. S., Catalfamo, M., Kimura, M. Y., Cui, Y., Lucas, P. J., Gress, R. E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1840 · Cited by 5,835
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
Thornton, A. M., & Shevach, E. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.287 · Cited by 2,639
CD4+CD25+ suppressor T cells: more questions than answers
Shevach, E. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri821 · Cited by 2,110
REGULATION OF IMMUNE RESPONSES BY TGF-β
Letterio, J. J., & Roberts, A. B. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.137 · Cited by 1,890
IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells
Fiorentino, D. F., Zlotnik, A., Vieira, P., Mosmann, T. R., Howard, M., Moore, K. W., & O’Garra, A. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.10.3444 · Cited by 1,865
Sharpe, A. H., & Freeman, G. J. (2002) · Nature Reviews Immunology · doi:10.1038/nri727 · Cited by 1,712
Asseman, C., Mauze, S., Leach, M. W., Coffman, R. L., & Powrie, F. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.7.995 · Cited by 1,615
Nakamura, K., Kitani, A., & Strober, W. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.5.629 · Cited by 1,594
Research works printed but not linked: 4
- 10.1002/1521-4141(200106)31:6<1637::AID-IMMU1637>3.0.CO;2-T · doi:10.1002/1521-4141(200106)31:6<1637::aid-immu1637>3.0.co;2-t
- 10.1002/1521-4141(200104)31:4<1122::AID-IMMU1122>3.0.CO;2-P · DOI · Paper page
- 10.1002/1521-4141(200104)31:4<1247::AID-IMMU1247>3.0.CO;2-M · DOI · Paper page
- 10.1002/1521-4141(200003)30:3<876::AID-IMMU876>3.0.CO;2-M · doi:10.1002/1521-4141(200003)30:3<876::aid-immu876>3.0.co;2-m
Cited by
Ghiringhelli, F., Larmonier, N., Schmitt, E., Parcellier, A., Cathelin, D., Garrido, C., Chauffert, B., Solary, E., Bonnotte, B., & Martin, F. (2004) · European Journal of Immunology · doi:10.1002/eji.200324181 · Cited by 880
Weirather, J., Hofmann, U. D. W., Beyersdorf, N., Ramos, G. C., Vogel, B., Frey, A., Ertl, G., Kerkau, T., & Frantz, S. (2014) · Circulation Research · doi:10.1161/circresaha.115.303895 · Cited by 699
Immunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D. M., & Chen, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2051 · Cited by 627
An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection
Cabrera, R., Tu, Z., Xu, Y., Firpi, R. J., Rosen, H. R., Liu, C., & Nelson, D. R. (2004) · Hepatology · doi:10.1002/hep.20454 · Cited by 562
Large-scale in vitro expansion of polyclonal human CD4+CD25high regulatory T cells
Hoffmann, P., Eder, R., Kunz-Schughart, L. A., Andreesen, R., & Edinger, M. (2004) · Blood · doi:10.1182/blood-2004-01-0086 · Cited by 494
Human T Regulatory Cell Therapy: Take a Billion or So and Call Me in the Morning
Riley, J. L., June, C. H., & Blazar, B. R. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.006 · Cited by 412
Human regulatory T cells: role in autoimmune disease and therapeutic opportunities
Brusko, T. M., Putnam, A. L., & Bluestone, J. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00637.x · Cited by 374
Ronchetti, S., Zollo, O., Bruscoli, S., Agostini, M., Bianchini, R., Nocentini, G., Ayroldi, E., & Riccardi, C. (2004) · European Journal of Immunology · doi:10.1002/eji.200324804 · Cited by 359
Transient regulatory T-cells: A state attained by all activated human T-cells
Pillai, V., Ortega, S. B., Wang, C. K., & Karandikar, N. J. (2007) · Clinical Immunology · doi:10.1016/j.clim.2006.10.014 · Cited by 339
Eastwood, D., Findlay, L., Poole, S., Bird, C., Wadhwa, M., Moore, M., Burns, C., Thorpe, R., & Stebbings, R. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00922.x · Cited by 300
The role of CD28 and cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) in regulatory T‐cell biology
Sansom, D. M., & Walker, L. S. K. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00419.x · Cited by 293
Godfrey, W. R., Ge, Y. G., Spoden, D. J., Levine, B. L., June, C. H., Blazar, B. R., & Porter, S. B. (2004) · Blood · doi:10.1182/blood-2004-01-0151 · Cited by 277
Estes, J. D., Li, Q., Reynolds, M. R., Wietgrefe, S., Duan, L., Schacker, T., Picker, L. J., Watkins, D. I., Lifson, J. D., Reilly, C., et al. (2006) · The Journal of Infectious Diseases · doi:10.1086/500368 · Cited by 237
Oldenhove, G., de Heusch, M., Urbain-Vansanten, G., Urbain, J., Maliszewski, C., Leo, O., & Moser, M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030654 · Cited by 225
Bour‐Jordan, H., & Bluestone, J. A. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00775.x · Cited by 223
Regulatory T Cells Protect from Local and Systemic Bone Destruction in Arthritis
Zaiss, M. M., Frey, B., Hess, A., Zwerina, J., Luther, J., Nimmerjahn, F., Engelke, K., Kollias, G., Hünig, T., Schett, G., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903841 · Cited by 205
Self-citationBeyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203
“Moreover, we could demonstrate that superagonistic mAbs to CD28 are capable of expanding functional CD4 CD25 T reg cells (15), suggesting that CD28 superagonist therapy may be highly effective in the treatment of inflammatory and autoimmune diseases.”
BackgroundMethodSelf-citationThe storm has cleared: lessons from the CD28 superagonist TGN1412 trial
Hünig, T. (2012) · Nature Reviews Immunology · doi:10.1038/nri3192 · Cited by 194
Self-citationTHOMPSON, C. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.05.001 · Cited by 193
Regulatory T Cells and Human Disease
Cools, N., Ponsaerts, P., Van Tendeloo, V. F. I., & Berneman, Z. N. (2007) · Clinical and Developmental Immunology · doi:10.1155/2007/89195 · Cited by 190
Challenges and approaches for the development of safer immunomodulatory biologics
Sathish, J. G., Sethu, S., Bielsky, M.-C., de Haan, L., French, N. S., Govindappa, K., Green, J., Griffiths, C. E. M., Holgate, S., Jones, D., et al. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3974 · Cited by 185
Austin, P. J., Kim, C. F., Perera, C. J., & Moalem-Taylor, G. (2012) · Pain · doi:10.1016/j.pain.2012.06.005 · Cited by 180
Homogeneous Expansion of Human T-Regulatory Cells Via Tumor Necrosis Factor Receptor 2
Okubo, Y., Mera, T., Wang, L., & Faustman, D. L. (2013) · Scientific Reports · doi:10.1038/srep03153 · Cited by 170
The 4-1BB Costimulation Augments the Proliferation of CD4+CD25+ Regulatory T Cells
Zheng, G., Wang, B., & Chen, A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.4.2428 · Cited by 164
Skapenko, A., Kalden, J. R., Lipsky, P. E., & Schulze-Koops, H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.6107 · Cited by 157
Römer, P. S., Berr, S., Avota, E., Na, S.-Y., Battaglia, M., ten Berge, I., Einsele, H., & Hünig, T. (2011) · Blood · doi:10.1182/blood-2010-12-319780 · Cited by 153
Self-citationTreg(s) in Cancer: Friends or Foe?
Wolf, D., Sopper, S., Pircher, A., Gastl, G., & Wolf, A. M. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25016 · Cited by 151
Strategies to enhance T-cell reconstitution in immunocompromised patients
van den Brink, M. R. M., Alpdoğan, Ö., & Boyd, R. L. (2004) · Nature reviews. Immunology · doi:10.1038/nri1484 · Cited by 148
Regulatory T cells in human disease and their potential for therapeutic manipulation
Taams, L. S., Palmer, D. B., Akbar, A. N., Robinson, D. S., Brown, Z., & Hawrylowicz, C. M. (2006) · Immunology · doi:10.1111/j.1365-2567.2006.02348.x · Cited by 136
Na, S., Mracsko, E. Z., Liesz, A., Hünig, T., & Veltkamp, R. C. (2014) · Stroke · doi:10.1161/strokeaha.114.007756 · Cited by 128
Self-citationRegulatory T cells (Treg) in rheumatoid arthritis
Boissier, M., Assier, É., Biton, J., Denys, A., Falgarone, G., & Bessis, N. (2008) · Joint Bone Spine · doi:10.1016/j.jbspin.2008.08.002 · Cited by 123
Swee, L. K., Bosco, N., MALISSEN, B., Ceredig, R., & Rolink, A. G. (2009) · Blood · doi:10.1182/blood-2008-06-161026 · Cited by 126
T Regulatory Cells in Bone Remodelling
Bozec, A., & Zaiss, M. M. (2017) · Current Osteoporosis Reports · doi:10.1007/s11914-017-0356-1 · Cited by 110
Tabares, P., Berr, S., Römer, P. S., Chuvpilo, S., Matskevich, A. A., Tyrsin, D., Fedotov, Y., Einsele, H., Tony, H., & Hünig, T. (2014) · European Journal of Immunology · doi:10.1002/eji.201343967 · Cited by 97
Self-citationAlternative Strategies for Toxicity Testing of Species-Specific Biopharmaceuticals
Bussiere, J. L., Martin, P. L., Horner, M. J., Couch, J. A., Flaherty, M. M., Andrews, L., Beyer, J. C., & Horvath, C. J. (2009) · International Journal of Toxicology · doi:10.1177/1091581809337262 · Cited by 102
Harnaha, J., Machen, J., Wright, M. F., Lakomy, R., Styche, A. J., Trucco, M., Makaroun, S., & Giannoukakis, N. (2006) · Diabetes · doi:10.2337/diabetes.55.01.06.db05-0340 · Cited by 97
Clinical application of expanded CD4+25+ cells
June, C. H., & Blazar, B. R. (2006) · Seminars in Immunology · doi:10.1016/j.smim.2006.01.006 · Cited by 103
Wüest, T., Willette‐Brown, J., Durum, S. K., & Hurwitz, A. A. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.1107778 · Cited by 114
Schuhmann, M. K., Kraft, P., Stoll, G., Lorenz, K., Meuth, S. G., Wiendl, H., Nieswandt, B., Sparwasser, T. D., Beyersdorf, N., Kerkau, T., et al. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.175 · Cited by 96
Fcγ receptors and immunomodulatory antibodies in cancer
Gálvez‐Cancino, F., Simpson, A. P., Costoya, C., Matos, I. G., Qian, D., Peggs, K. S., Litchfield, K., & Quezada, S. A. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00637-8 · Cited by 104
Horvath, C. J., & Milton, M. N. (2009) · Toxicologic Pathology · doi:10.1177/0192623309332986 · Cited by 87
Costimulatory pathways in transplantation
Pilat, N., Sayegh, M. H., & Wekerle, T. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.04.002 · Cited by 93
Ex vivo expansion of CD4+CD25+ T regulatory cells for immunosuppressive therapy
Trzonkowski, P., Szaryńska, M., Myśliwska, J. M., & Myśliwski, A. (2008) · Cytometry Part A · doi:10.1002/cyto.a.20659 · Cited by 94
Tischner, D. (2006) · Brain · doi:10.1093/brain/awl213 · Cited by 82
Beyersdorf, N., Hanke, T., Kerkau, T., & Hünig, T. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.042564 · Cited by 98
Self-citationLegrand, N., Cupedo, T., van Lent, A. U., Ebeli, M. J., Weijer, K., Hanke, T., & Spits, H. (2006) · Blood · doi:10.1182/blood-2006-01-0190 · Cited by 82
Rapid Regulatory T-Cell Response Prevents Cytokine Storm in CD28 Superagonist Treated Mice
Gogishvili, T., Langenhorst, D., Lühder, F., Elias, F., Elflein, K., Dennehy, K. M., Gold, R., & Hünig, T. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004643 · Cited by 79
Self-citationSignaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies
Waibler, Z., Sender, L. Y., Merten, C., Hartig, R., Kliche, S., Gunzer, M., Reichardt, P., Kalinke, U., & Schraven, B. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001708 · Cited by 79
“Studies in rat and mice have also shown that CD28 superagonists preferentially induce the expansion of regulatory T cells and therefore suggested that these antibodies can be used for the treatment of autoimmune diseases such as experimental autoimmune encephalomyelitis [13–20].”
BackgroundAdjunct Immunotherapies for Tuberculosis
Uhlin, M., Andersson, J., Zumla, A. I., & Maeurer, M. J. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis197 · Cited by 80
Adeegbe, D. O., Bayer, A. L., Levy, R. B., & Malek, T. R. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.12.7149 · Cited by 74
After TGN1412: Recent developments in cytokine release assays
Stebbings, R., Eastwood, D., Poole, S., & Thorpe, R. (2013) · Journal of Immunotoxicology · doi:10.3109/1547691x.2012.711783 · Cited by 73
“…and adjuvant arthritis, treatment with anti-CD28 mAbs orthologous to TGN1412 stimulated the release of antiinflammatory cytokines and the expansion of regulatory T-cells believed to counter autoimmune responses (Rodríguez-Palmero et al., 1999; Lin and Hünig, 2003; Beyersdorf et al., 2005).”
BackgroundSafety of biologics, lessons learnt from TGN1412
Stebbings, R., Poole, S., & Thorpe, R. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.002 · Cited by 70
A TNFR2-Agonist Facilitates High Purity Expansion of Human Low Purity Treg Cells
He, X., Landman, S., Bauland, S. C. G., van den Dolder, J., Koenen, H. J. P. M., & Joosten, I. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156311 · Cited by 69
Hacquard‐Bouder, C., Falgarone, G., Bosquet, A., Smaoui, F., Monnet, D., Ittah, M., & Bréban, M. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20211 · Cited by 69
Impact of aging immune system on neurodegeneration and potential immunotherapies
Liang, Z., Zhao, Y., Ruan, L., Zhu, L., Jin, K., Zhuge, Q., Su, D., & Zhao, Y. L. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.07.006 · Cited by 67
Beyersdorf, N., Hanke, T., Kerkau, T., & Hünig, T. (2005) · Autoimmunity Reviews · doi:10.1016/j.autrev.2005.06.001 · Cited by 66
Self-citationSchmidt, J., Elflein, K., Stienekemeier, M., Rodriguez-Palmero, M., Schneider, C., Toyka, K. V., Gold, R., & Hünig, T. (2003) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(03)00182-6 · Cited by 59
“, 1999) suggested the activation of the ‘‘regulatory’’ subset of CD4 T cells (Lin and Hunig, 2003), which is thought to play a key role in counteracting autoimmunity and inflammation (Shevach, 2000).”
BackgroundMethodSelf-citationSignals and pathways controlling regulatory T cells
Huynh, A., Zhang, R., & Turka, L. A. (2014) · Immunological Reviews · doi:10.1111/imr.12148 · Cited by 66
Regulatory T cell therapy: Current and future design perspectives
Rana, J., & Biswas, M. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104193 · Cited by 61
CD28 Superagonists: What Makes the Difference in Humans?
Schraven, B. L., & Kalinke, U. (2008) · Immunity · doi:10.1016/j.immuni.2008.04.003 · Cited by 63
Severity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release
Eastwood, D., Bird, C., Dilger, P., Hockley, J., Findlay, L., Poole, S., Thorpe, S. J., Wadhwa, M., Thorpe, R., & Stebbings, R. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12165 · Cited by 58
Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies
Hünig, T. (2007) · Advances in Immunology · doi:10.1016/s0065-2776(07)95004-x · Cited by 57
Self-citationCD28 superagonists: Mode of action and therapeutic potential
Hünig, T., & Dennehy, K. M. (2005) · Immunology Letters · doi:10.1016/j.imlet.2005.06.012 · Cited by 63
Self-citationPorciello, N., & Tuosto, L. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.02.004 · Cited by 61
Soto, P. C., Stein, L. L., Hurtado-Ziola, N., Hedrick, S. M., & Varki, A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903420 · Cited by 56
van den Brandt, J., Fischer, H. J., Walter, L., Hünig, T., Klöting, I., & Reichardt, H. M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000462 · Cited by 54
Self-citationA more selective costimulatory blockade of the CD28-B7 pathway
Poirier, N., Blancho, G., & Vanhove, B. (2010) · Transplant International · doi:10.1111/j.1432-2277.2010.01176.x · Cited by 54
Toxicity as a result of immunostimulation by biologics
Gribble, E. J., Sivakumar, P. V., Ponce, R. A., & Hughes, S. D. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.3.2.209 · Cited by 52
The rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account
Hünig, T. (2016) · The FEBS Journal · doi:10.1111/febs.13754 · Cited by 47
Self-citationCD28-Specific Immunomodulating Antibodies: What Can Be Learned From Experimental Models?
Poirier, N., Blancho, G., & Vanhove, B. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04032.x · Cited by 52
A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats
Müller, N., van den Brandt, J., Odoardi, F., Tischner, D., Herath, J., Flügel, A., & Reichardt, H. M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32698 · Cited by 46
Cutting Edge: Monovalency of CD28 Maintains the Antigen Dependence of T Cell Costimulatory Responses
Dennehy, K. M., Elias, F., Zeder-Lutz, G., Ding, X., Altschuh, D., Lühder, F., & Hünig, T. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.10.5725 · Cited by 46
Self-citationCamperio, C., Muscolini, M., Volpe, E., Mitri, D. D., Mechelli, R., Buscarinu, M. C., Ruggieri, S., Piccolella, E., Salvetti, M., Gasperini, C., et al. (2014) · Immunology Letters · doi:10.1016/j.imlet.2013.12.020 · Cited by 47
TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model
Weißmüller, S., Kronhart, S., Kreuz, D., Schnierle, B. S., Kalinke, U., Kirberg, J., Hanschmann, K.-M. O., & Waibler, Z. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149093 · Cited by 45
Guilliams, M., Bosschaerts, T., Hérin, M., Hünig, T., Loi, P., Flamand, V., De Baetselier, P., & Beschin, A. (2008) · The Journal of Infectious Diseases · doi:10.1086/590439 · Cited by 43
Self-citationT-cell co-stimulatory molecules: their role in allergic immune reactions
Kallinich, T., Beier, K. C., Wahn, U., Stock, P., & Hamelmann, E. H. (2007) · European Respiratory Journal · doi:10.1183/09031936.00094306 · Cited by 47
Costimulation Blockade in Kidney Transplantation: An Update
Malvezzi, P., Jouvé, T., & Rostaing, L. P. E. (2016) · Transplantation · doi:10.1097/tp.0000000000001344 · Cited by 47
Kitazawa, Y., Fujino, M., Li, X.-K., Xie, L., Ichimaru, N., Okumi, M., Nonomura, N., Tsujimura, A., Isaka, Y., Kimura, H., et al. (2009) · Cell Transplantation · doi:10.1177/096368970901805-619 · Cited by 41
Self-citationSingle CD28 stimulation induces stable and polyclonal expansion of human regulatory T cells
He, X., Smeets, R. L., van Rijssen, E., Boots, A. M. H., Joosten, I., & Koenen, H. J. P. M. (2017) · Scientific Reports · doi:10.1038/srep43003 · Cited by 38
Targeting regulatory T cells for cardiovascular diseases
Wang, X., Zhou, H., Liu, Q., Cheng, P., Zhao, T., Yang, T., Zhao, Y., Sha, W., Zhao, Y., & Qu, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1126761 · Cited by 41
Helling, B., König, M. F., Dälken, B., Engling, A., Krömer, W., Heim, K., Wallmeier, H., Haas, J., Wildemann, B., Fritz, B., et al. (2014) · Immunology and Cell Biology · doi:10.1038/icb.2014.102 · Cited by 38
Identification, Isolation, and Functional Assay of Regulatory T Cells
Azimi, M., Aslani, S., Mortezagholi, S., Farrokhi, A. S., Javan, M. R., Rezaiemanesh, A., Ghaedi, M., Gholamzad, M., & Salehi, E. (2016) · Immunological Investigations · doi:10.1080/08820139.2016.1193869 · Cited by 39
Regulatory CD4 T cells: sensing the environment
Matarese, G., Rosa, V. D., & Cava, A. L. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.10.006 · Cited by 37
Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial
Horvath, C. J., Andrews, L., Baumann, A., Black, L. E., Blanset, D. L., Cavagnaro, J. A., Hastings, K. L., Hutto, D., MacLachlan, T. K., Milton, M., et al. (2012) · Nature reviews. Immunology · doi:10.1038/nri3192-c1 · Cited by 41
Friend or foe: the dichotomous impact of T cells on neuro-de/re-generation during aging
Coder, B., Wang, W., Wang, L., Wu, Z., Zhuge, Q., & Su, D.-M. (2017) · Oncotarget · doi:10.18632/oncotarget.12572 · Cited by 36
Superagonistic CD28 stimulation of allogeneic T cells protects from acute graft-versus-host disease
Beyersdorf, N., Ding, X., Hünig, T., & Kerkau, T. (2009) · Blood · doi:10.1182/blood-2009-04-218248 · Cited by 35
Self-citationPhenotypic characterization of regulatory CD4+CD25+ T cells in rats
Stephens, L. A., Barclay, A. N., & Mason, D. (2004) · International Immunology · doi:10.1093/intimm/dxh033 · Cited by 40
A non-conserved amino acid variant regulates differential signalling between human and mouse CD28
Porciello, N., Grazioli, P., Campese, A. F., Kunkl, M., Caristi, S., Mastrogiovanni, M., Muscolini, M., Spadaro, F., Favre, C., Nunès, J. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03385-8 · Cited by 37
Control of Regulatory T Cells by Co-signal Molecules
Wing, J. B., Tay, C., & Sakaguchi, S. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9717-3_7 · Cited by 37
The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases
Carballido, J. M., Regairaz, C., Rauld, C., Raad, L., Picard, D., & Kammuller, M. E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00472 · Cited by 40
Can preclinical drug development help to predict adverse events in clinical trials?
Chi, L. H., Burrows, A. D., & Anderson, R. L. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.08.010 · Cited by 34
Zhang, R.-M., Xi, X., Wang, C., Pan, Y., Ge, C., Zhang, L., Zhang, S., & Liu, H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201025 · Cited by 32
Kanai∥, T., & Watanabe, M. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.4.451 · Cited by 34
Depleting T-cell subpopulations in organ transplantation: T-cell depletion and tolerance
Haudebourg, T., Poirier, N., & Vanhove, B. (2008) · Transplant International · doi:10.1111/j.1432-2277.2008.00788.x · Cited by 35
Co-stimulate or Co-inhibit Regulatory T Cells, Which Side to Go?
Liu, W., Almo, S. C., & Zang, X. (2016) · Immunological Investigations · doi:10.1080/08820139.2016.1186690 · Cited by 34
Schmidt, T., Willenborg, S., Hünig, T., Deeg, C. A., Sønderstrup, G., Hertl, M., & Eming, R. (2015) · Experimental Dermatology · doi:10.1111/exd.12919 · Cited by 31
Self-citationParalysis of CD4+CD25+ regulatory T cell response in chronic autoimmune encephalomyelitis
Matsumoto, Y., Sakuma, H., Kohyama, K., & Park, I.-K. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2007.04.004 · Cited by 29
Low-dose IL-2 shapes a tolerogenic gut microbiota that improves autoimmunity and gut inflammation
Tchitchek, N., Tchoumba, O. F. N., Pires, G., Dandou, S., Campagne, J., Churlaud, G., Fourcade, G., Hoffmann, T. W., Strozzi, F., Gaal, C., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.159406 · Cited by 29
Beyersdorf, N., Ding, X., Blank, G., Dennehy, K. M., Kerkau, T., & Hünig, T. (2008) · Blood · doi:10.1182/blood-2008-03-146662 · Cited by 32
Self-citationAnimal extrapolation in preclinical studies: An analysis of the tragic case of TGN1412
Lemoine, M. (2016) · Studies in History and Philosophy of Science Part C Studies in History and Philosophy of Biological and Biomedical Sciences · doi:10.1016/j.shpsc.2016.12.004 · Cited by 28
Metadata
- Authors
- Lin, C., & Hünig, T.
- Affiliations
- University of Würzburg (DE)
- Corresponding author
- Hünig, Thomas
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 2003-02-17
- Volume
- 33
- Issue
- 3
- Pages
- 626-638
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W1992139204
- Cited by
- 184
- References
- 44
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 4 · 2022: 4 · 2021: 5 · 2020: 4 · 2019: 3 · 2018: 5 · 2017: 7 · 2016: 11 · 2015: 8 · 2014: 10 · 2013: 6 · 2012: 11
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- regulatory T cells, CD28 costimulation, CTLA-4, CD4+CD25+ T cells, Treg cell expansion, Treg suppressive function, IL-10, autoimmune disease therapy, inflammatory disease therapy, T cell activation
- MeSH terms
- Abatacept, Animals, Antigens, Differentiation, Interleukin-2, Mice, Inbred BALB C, Rats, Inbred Lew, T-Lymphocytes, Receptors, Interleukin-2, Antigens, CD, CD4 Antigens, Interleukin-10, CD28 Antigens, Immunoconjugates, T-Lymphocytes, Regulatory, Mice, Rats, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.